Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Revolution Medicines, Inc. (RVMD) provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed late-stage clinical oncology company, Revolution Medicines uses these filings to report on its financial condition, clinical and regulatory milestones, and significant corporate agreements related to its RAS(ON) inhibitor pipeline.
Investors reviewing RVMD’s filings will find current reports on Form 8-K that describe material events such as clinical data updates, FDA designations and strategic financings. For example, the company has filed 8-Ks detailing Breakthrough Therapy Designation and a Commissioner’s National Priority Voucher for daraxonrasib, pipeline updates in pancreatic ductal adenocarcinoma and non-small cell lung cancer, and a Royalty Purchase Agreement with Royalty Pharma covering potential future net product sales of daraxonrasib and zoldonrasib.
Other 8-K filings discuss term loan facilities linked to regulatory approvals and sales milestones, leadership changes at the board and executive levels, and the listing of Revolution Medicines’ common stock (RVMD) and warrants (RVMDW) on The Nasdaq Stock Market LLC. Periodic filings such as Forms 10-Q and 10-K, referenced in the company’s forward-looking statements, provide more comprehensive discussions of risk factors, research and development activities, and overall business strategy.
On Stock Titan, these SEC filings are presented with real-time updates from EDGAR and AI-powered summaries that highlight key points, such as how financing agreements relate to daraxonrasib and zoldonrasib, or what new clinical or regulatory information is disclosed. Users can quickly identify items related to quarterly results (10-Q), annual reports (10-K), and current reports (8-K), as well as monitor registered securities like RVMD and RVMDW.
This page helps readers understand how Revolution Medicines reports on its RAS(ON) inhibitor programs, financial position and significant corporate events through its SEC disclosures, with AI tools simplifying navigation of complex oncology and financing information.
Mark A. Goldsmith provided notice under Form 144 of proposed transactions in common stock. The filing shows a prior sale of 15,394 common shares on
Revolution Medicines, Inc. is registering shares of its common stock for sale under a replacement at-the-market sales agreement with TD Securities (USA) LLC to offer up to
The sales agreement, dated
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on small-molecule drugs that directly inhibit activated RAS proteins in cancer. It reported that it remains pre-revenue, expects continued losses and will require substantial additional financing to advance its pipeline.
The company’s lead RAS(ON) inhibitor, daraxonrasib (RMC-6236), is in multiple global Phase 3 trials for pancreatic cancer and a Phase 3 trial for RAS‑mutant non-small cell lung cancer and has U.S. FDA Breakthrough Therapy and Orphan Drug designations in pancreatic settings. Zoldonrasib and elironrasib also hold Breakthrough Therapy designations in specific KRAS‑mutant lung cancer populations.
Early‑phase data across pancreatic, lung and colorectal cancers showed objective response rates generally ranging from the mid‑20% range to above 60% in selected settings, with high disease control rates. Revolution Medicines is also advancing additional mutant‑selective RAS(ON) agents, planning a new RAS(ON) inhibitor class, and expanding collaborations with Amgen, Bristol Myers Squibb, Summit, Tango and others.
Revolution Medicines reported larger losses for the fourth quarter and full year 2025 as it ramped investment in its late-stage oncology pipeline. Fourth-quarter net loss was $364.9 million, compared with $194.6 million a year earlier, and full-year net loss reached $1.1 billion versus $600.1 million.
Research and development expenses grew to $987.3 million in 2025 and general and administrative costs to $195.0 million, reflecting multiple Phase 3 programs and commercial preparation. The company ended 2025 with $2.0 billion in cash, cash equivalents and marketable securities and has $1.75 billion of additional committed capital from its Royalty Pharma arrangement.
The pipeline now includes five ongoing Phase 3 trials and several more planned for 2026 across pancreatic, lung and colorectal cancers, centered on its RAS(ON) inhibitors daraxonrasib, zoldonrasib and elironrasib. For 2026, Revolution Medicines guides to GAAP operating expenses of $1.6–$1.7 billion, including $180–$200 million of non-cash stock-based compensation.
Revolution Medicines, Inc. received an amended Schedule 13G filing from Baker Bros. entities reporting their ownership of its common stock. Baker Bros. Advisors LP, its general partner Baker Bros. Advisors (GP) LLC, and principals Julian and Felix Baker together report beneficial ownership of 9,455,357 shares of common stock, representing 4.9% of the class.
The filing explains that these shares are held through funds 667, L.P. and Baker Brothers Life Sciences, L.P., which directly hold 784,767 and 8,670,590 shares, respectively. The ownership percentage is based on 193,319,805 shares outstanding as of October 31, 2025, and the securities are described as being held in the ordinary course of business, without the purpose of changing or influencing control of the company.
Revolution Medicines President and CEO Mark A. Goldsmith, who also serves as a director, reported an option exercise and updated share holdings. On February 6, 2026, a stock option for 24,010 shares with a $0.54 exercise price was converted into the same number of common shares.
Following the transaction, Goldsmith directly held 256,479 shares of common stock, which the filing notes includes 168,763 restricted stock units570,050 shares in the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust and 67,424 shares in each of two additional revocable trusts.
Revolution Medicines, Inc. received an amended Schedule 13G from several Wellington-affiliated entities reporting their beneficial ownership of its common stock as of December 31, 2025. The filing shows aggregate beneficial ownership of 6,987,639 shares, representing about 3.6%–3.61% of the outstanding common stock.
Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP report shared voting power over 6,128,704 shares and shared dispositive power over 6,987,639 shares, with no sole voting or dispositive power. The securities are owned of record by clients of various Wellington investment advisers, who retain the economic benefits. The filing states the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Revolution Medicines.
Revolution Medicines, Inc. received an Amendment No. 3 to a Schedule 13G from a group of Farallon-managed funds and related entities reporting a sizable passive ownership position in its common stock.
The Farallon funds report beneficial ownership of an aggregate 14,582,796 Shares of common stock, plus 120,085 Common Stock Purchase Warrants, each exercisable to purchase 0.1112 Share, subject to a 9.99% Beneficial Ownership Limitation. Based on the cover pages, several Farallon entities and individual reporting persons each report beneficial ownership of approximately 7.5% of the class, with Farallon Partners, L.L.C. reporting 7.4%.
The filing also updates who is deemed to beneficially own these holdings. Effective January 1, 2026, Avner A. Husen became a member or manager of the Farallon general partner entities and may be deemed a beneficial owner of the Farallon funds’ Shares and Warrants. Effective December 31, 2025, Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles and may no longer be deemed beneficial owners.
The reporting persons certify the securities were acquired and are held without the purpose or effect of changing or influencing control of Revolution Medicines, other than activities solely in connection with a nomination under the stated SEC rule.
Revolution Medicines’ general counsel, Jeff Cislini, reported a small, pre-planned stock sale. On January 21, 2026, he sold 908 shares of Revolution Medicines common stock at $115.60 per share under a Rule 10b5-1 trading plan adopted on March 13, 2025. After this sale, he beneficially owned 46,976 shares, which include 38,769 restricted stock units that typically vest over time.
Revolution Medicines shareholder Jeffrey Todd Cislini has filed a notice to sell common stock. The filing covers a planned sale of 908 common shares through Morgan Stanley Smith Barney LLC on or around 01/21/2026 on the NASDAQ market. These shares were acquired as restricted stock units from the issuer on 12/15/2025, and the block has an aggregate market value of $105,527.76.
The notice states that Revolution Medicines had 193,319,805 common shares outstanding at the time referenced. Over the prior three months, Cislini sold 2,688 common shares on 12/16/2025 for $206,483.83 and 13,388 common shares on 11/18/2025 for $939,008.57, with the larger transaction noted as Rule 10b5-1 sales. By signing, the seller represents they are not aware of undisclosed material adverse information about the company’s operations.